TILANX Trademark

Trademark Overview

On Tuesday, February 21, 2017, a trademark application was filed for TILANX with the United States Patent and Trademark Office. The USPTO has given the TILANX trademark a serial number of 87343865. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 18, 2021. This trademark is owned by Pfizer Inc.. The TILANX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use
tilanx

General Information

Serial Number87343865
Word MarkTILANX
Filing DateTuesday, February 21, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 18, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 17, 2017

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 28, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Tuesday, January 19, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 18, 2021ABANDONMENT - NO USE STATEMENT FILED
Thursday, May 14, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 13, 2020EXTENSION 5 GRANTED
Friday, May 1, 2020EXTENSION 5 FILED
Wednesday, May 13, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, May 1, 2020TEAS EXTENSION RECEIVED
Thursday, February 13, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 13, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, January 30, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, January 30, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, December 5, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 3, 2019EXTENSION 4 GRANTED
Tuesday, December 3, 2019EXTENSION 4 FILED
Tuesday, December 3, 2019TEAS EXTENSION RECEIVED
Tuesday, November 26, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, November 26, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, May 18, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 16, 2019EXTENSION 3 GRANTED
Thursday, May 16, 2019EXTENSION 3 FILED
Thursday, May 16, 2019TEAS EXTENSION RECEIVED
Tuesday, December 4, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 30, 2018EXTENSION 2 GRANTED
Friday, November 30, 2018EXTENSION 2 FILED
Friday, November 30, 2018TEAS EXTENSION RECEIVED
Thursday, May 10, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 8, 2018EXTENSION 1 GRANTED
Tuesday, May 8, 2018EXTENSION 1 FILED
Tuesday, May 8, 2018TEAS EXTENSION RECEIVED
Tuesday, December 12, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 17, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 17, 2017PUBLISHED FOR OPPOSITION
Wednesday, September 27, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, September 9, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, September 8, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, September 7, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, September 7, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, April 10, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, April 10, 2017NON-FINAL ACTION E-MAILED
Monday, April 10, 2017NON-FINAL ACTION WRITTEN
Monday, April 10, 2017ASSIGNED TO EXAMINER
Tuesday, February 28, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, February 24, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

tilanx preparations pharmaceutical dysfunction treatment cancer diabetes sexual pain disorders diseases